CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

Casgevy UptakeCasgevy, the company’s gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia, generated $54 million in fourth-quarter revenue and $116 million for the full year.A total of 64 patients received infusions in 2025, including 30 during the fourth quarter.Globally, 147 patients initiated treatment through the first cell collection during the year. Patient initiations nearly tripled compared to 2024, reflecting growing momentum heading into 2026.William Blair noted, ...